Shares of Pharvaris N.V. (NASDAQ: PHVS) tumbled 5.15% in intraday trading, as investors reacted to the company's disappointing first-quarter financial results and a subsequent analyst price target reduction.
The clinical-stage biopharmaceutical company reported quarterly losses of $0.89 per share, missing the analyst consensus estimate of $0.82 by 8.54%. This represents a significant increase in losses compared to the same period last year when the company reported a loss of $0.56 per share. The wider-than-expected loss appears to have shaken investor confidence in the company's financial performance.
Adding to the downward pressure, Wedbush, a prominent financial services firm, adjusted its price target for Pharvaris from $25 to $17. Despite the lower target, Wedbush maintained its Outperform rating on the stock, suggesting a mixed outlook for the company. It's worth noting that Pharvaris still maintains an average rating of Buy among analysts, with a mean price target of $33.13, indicating potential long-term optimism despite the current setback.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.